#Communiqué | Test sanguin : la HAS recommande de ne plus prescrire la vitesse de sédimentation. 👉 https://t.co/9s68iafLwC

The latest Nature Medicine feature on open-label placebos is another reminder of how powerful the mind–body connection truly is. Even when patients know they’re taking an inert treatment, many still experience real improvements, in pain, mood, and overall wellbeing. This

@davidmcw Well the current expenditure isn’t going on cutting edge cancer treatments..probably lots of these graphs are out there for different areas that impact people’s lives

🧬 Durvalumab ± tremelimumab + chemo improves OS vs chemo alone in 1L mNSCLC (POSEIDON, 5y FU). Benefit stronger in TMB-high pts. Adding anti-CTLA-4 may enhance response in this group. 📖 @ESMO_Open @peters_solange 👉🏻 https://t.co/k43JYwqPPK #NSCLC #Immunotherapy #TMB

📢 Renouvellement du Conseil Scientifique de l’IFCT ➡️ 26 membres nommés pour 2 ans afin d’orienter, d'améliorer les travaux de recherche & de favoriser les collaborations interdisciplinaires au sein de notre communauté académique : https://t.co/IIXP6HDaho

🫁 #Ivonescimab - HARMOi-A, #EGFR mut #NSCLC 🫁 🫁 Final OS 🫁 @sitcancer #SITC25 @LeXiuning

Chromosome 15q15 Deletion drives brain mets in NSCLC Using 3 independent NSCLC cohorts (multi-omics study: WGS/WES, RNA seq; n=1081) 15q15 deletion was identified as a driver of brain mets in NSCLC in EGFR tumors (~60%). Loss of MGA activates MYC–OXPHOS signaling, ↑↑ BM risk

Retreatment, rechallenge, and escalation with subsequent ICI therapies across cancers after initial failure 📌The strongest responses were observed in melanoma, while efficacy in other tumors (e.g., RCC, NSCLC, urothelial carcinoma) was limited with low-level evidence. Overall,

🚨 Why do some young, never-smoker Asians develop lung adenocarcinoma? New JTO study sheds light 🔍 🧬 Whole-exome/genome sequencing of 10,000+ LADC cases identified key germline drivers: •TP53 GPVs → 2.9 % in early-onset (< 40 y) vs 0.14 % later-onset •BRCA2 GPVs → 1.7 %

A l'occasion de Novembre Perle #LungcancerAwarenessMonth, retrouvez une sélection des initiatives locales réalisées avec la participation de membres investigateurs de l'IFCT et/ou des associations @reseauKpoumon et @AlkRos1France : https://t.co/Irqg7G8BxF #cancer #poumon

Unfortunately, while DLL3 is widely expressed (93%+) in tumors post-SCLC transformation ( https://t.co/ySAC2zeX7g), it is not clearly an actionable or biologically relevant target for transformed SCLC. This is similar to EGFR alterations and anti-PD-1/PD-L1 therapies, despite high

🚨 EGFR+ NSCLC: Who truly benefits from 1L osimertinib monotherapy? 🧬💊 New Hong Kong real-world study (n=282) finds: 👩‍⚕️ 37% developed oligoprogression (≤5 sites) 🩻 OPD → longer TTF (26 vs 14 mo) & OS (35 vs 25 mo) vs systemic PD 🎯 Local ablative therapy (LAT) prolonged

Disappointing early look at tarlatamab in #EGFR NSCLC after #SCLC transformation @JCOPO_ASCO from @alissajcooper et al. Small numbers but out of 14, only 1 response (7%). May reflect heavy pretreatment and PS but optimism somewhat tempered here. https://t.co/7GKaaXgHp2

It’s Lung Cancer Awareness Month! 🤍 Lung cancer remains the #1 cancer killer worldwide, but millions of patients, clinicians, and researchers are fighting back every day. Join them. Support the IASLC Foundation. Donate now: https://t.co/BcrFYsuhRJ

🫁 November is Lung Cancer Awareness Month! Lung cancer remains the #1 cancer killer worldwide, and recent studies show a rising number of cases in young adults-many of them non-tobacco users. This month, we are raising awareness about lung cancer in young people. Stay tuned💙

🫁 Consensus surveys about respectability 🫁 🇪🇺 #EORTC 🇺🇸 #STS 🇯🇵🇨🇳🇰🇷 #FACO 🫁 Not all the same 🫁 #lungcancer #nsclc #surgery #LCSM

A trio of clinicians who believe in the importance of medical radiation share their thoughts on the UCSF report that created public hysteria about CT scans. https://t.co/cHZqPmrqBs

🚨New from #HauraLab @Hitendras08 @MoffittNews : In #KRASG12C NSCLC models, resistance to KRAS G12C (OFF) inhibitors can be overcome by RAS-GTP (ON) inhibition highlighting news strategies to counter adaptive RAS signaling 🔬💥 see full paper below: 👇🏼👇🏼👇🏼👇🏼👇🏼 @AACR

Do the survival benefits outweigh the toxicity?

Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC (Mariposa trial🦋) https://t.co/MKgJRtHjVD